Literature DB >> 25578953

Functional MRI and CT biomarkers in oncology.

J M Winfield1, G S Payne, N M deSouza.   

Abstract

Imaging biomarkers derived from MRI or CT describe functional properties of tumours and normal tissues. They are finding increasing numbers of applications in diagnosis, monitoring of response to treatment and assessment of progression or recurrence. Imaging biomarkers also provide scope for assessment of heterogeneity within and between lesions. A wide variety of functional parameters have been investigated for use as biomarkers in oncology. Some imaging techniques are used routinely in clinical applications while others are currently restricted to clinical trials or preclinical studies. Apparent diffusion coefficient, magnetization transfer ratio and native T1 relaxation time provide information about structure and organization of tissues. Vascular properties may be described using parameters derived from dynamic contrast-enhanced MRI, dynamic contrast-enhanced CT, transverse relaxation rate (R2*), vessel size index and relative blood volume, while magnetic resonance spectroscopy may be used to probe the metabolic profile of tumours. This review describes the mechanisms of contrast underpinning each technique and the technical requirements for robust and reproducible imaging. The current status of each biomarker is described in terms of its validation, qualification and clinical applications, followed by a discussion of the current limitations and future perspectives.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25578953     DOI: 10.1007/s00259-014-2979-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  139 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Magnetization transfer analysis of brain tumor, infection, and infarction.

Authors:  M H Pui
Journal:  J Magn Reson Imaging       Date:  2000-09       Impact factor: 4.813

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer.

Authors:  J Glaholm; M O Leach; D J Collins; J Mansi; J C Sharp; A Madden; I E Smith; V R McCready
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

Review 5.  Diffusion-weighted magnetic resonance imaging and its application to cancer.

Authors:  Elizabeth M Charles-Edwards; Nandita M deSouza
Journal:  Cancer Imaging       Date:  2006-09-13       Impact factor: 3.909

Review 6.  A review of 1H nuclear magnetic resonance relaxation in pathology: are T1 and T2 diagnostic?

Authors:  P A Bottomley; C J Hardy; R E Argersinger; G Allen-Moore
Journal:  Med Phys       Date:  1987 Jan-Feb       Impact factor: 4.071

7.  Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

Authors:  Paul Nathan; Martin Zweifel; Anwar R Padhani; Dow-Mu Koh; Matthew Ng; David J Collins; Adrian Harris; Craig Carden; Jon Smythe; Nita Fisher; N Jane Taylor; J James Stirling; Shiao-Ping Lu; Martin O Leach; Gordon J S Rustin; Ian Judson
Journal:  Clin Cancer Res       Date:  2012-05-29       Impact factor: 12.531

8.  Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.

Authors:  Paul M J McSheehy; Claudia Weidensteiner; Catherine Cannet; Stephane Ferretti; Didier Laurent; Stephan Ruetz; Michael Stumm; Peter R Allegrini
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.

Authors:  Deepak Sampath; Jason Oeh; Shelby K Wyatt; Tim C Cao; Hartmut Koeppen; Jeffrey Eastham-Anderson; Liliane Robillard; Calvin C K Ho; Jed Ross; Guanglei Zhuang; Hani Bou Reslan; Philip Vitorino; Kai H Barck; Sharon E Ungersma; Jean Michel Vernes; Maresa Caunt; Nick Van Bruggen; Weilan Ye; Ulka Vijapurkar; Yu-Ju Gloria Meng; Napoleone Ferrara; Lori S Friedman; Richard A D Carano
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

10.  Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.

Authors:  I M E Desar; E G W ter Voert; Th Hambrock; J J A van Asten; D J van Spronsen; P F A Mulders; A Heerschap; W T A van der Graaf; H W M van Laarhoven; C M L van Herpen
Journal:  Cancer Imaging       Date:  2012-01-12       Impact factor: 3.909

View more
  8 in total

1.  MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent.

Authors:  Annasofia Anemone; Lorena Consolino; Dario Livio Longo
Journal:  Eur Radiol       Date:  2016-08-29       Impact factor: 5.315

Review 2.  Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.

Authors:  Matthias R Benz; Hebert Alberto Vargas; Evis Sala
Journal:  Magn Reson Imaging Clin N Am       Date:  2015-09-26       Impact factor: 2.266

3.  Use of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot Study.

Authors:  M Beth McCarville; Jamie L Coleman; Junyu Guo; Yimei Li; Xingyu Li; Patricia J Honnoll; Andrew M Davidoff; Fariba Navid
Journal:  AJR Am J Roentgenol       Date:  2016-03-21       Impact factor: 3.959

4.  Tumor Microenvironment Modifications Recorded With IVIM Perfusion Analysis and DCE-MRI After Neoadjuvant Radiotherapy: A Preclinical Study.

Authors:  François Lallemand; Natacha Leroi; Silvia Blacher; Mohamed Ali Bahri; Evelyne Balteau; Philippe Coucke; Agnès Noël; Alain Plenevaux; Philippe Martinive
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

5.  Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Authors:  Joo Ern Ang; Rupinder Pandher; Joo Chew Ang; Yasmin J Asad; Alan T Henley; Melanie Valenti; Gary Box; Alexis de Haven Brandon; Richard D Baird; Lori Friedman; Mika Derynck; Bart Vanhaesebroeck; Suzanne A Eccles; Stan B Kaye; Paul Workman; Johann S de Bono; Florence I Raynaud
Journal:  Mol Cancer Ther       Date:  2016-04-05       Impact factor: 6.261

6.  The Value of MR-DWI and T1 Mapping in Indicating Radiation-Induced Soft Tissue Injury.

Authors:  Zeng Wang; Bowen Xiong; Nannan Kang; Xiaoxian Pan; Caihong Wang; Li Su; Zhen Xing; Jinsheng Hong
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

7.  Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma.

Authors:  Shuai Wang; Junheng Li; Diru Zhu; Ting Hua; Binghui Zhao
Journal:  Quant Imaging Med Surg       Date:  2020-05

8.  Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.

Authors:  Filip Bochner; Liat Fellus-Alyagor; Dafna Ketter; Ofra Golani; Inbal Biton; Michal Neeman
Journal:  Br J Cancer       Date:  2020-05-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.